CYP17A1 rs121908081: Understanding Rare Genetic Variants
The rs121908081 variant is a rare genetic change located within the CYP17A1 gene. It is associated with disruptions in the body's ability to synthesize essential steroid hormones, which can lead to specific clinical conditions involving adrenal function and sexual development.
What each genotype means
Typical CYP17A1 function
This genotype represents the common, functional version of the CYP17A1 gene. Individuals with this profile typically produce the enzyme necessary for normal adrenal and gonadal steroid synthesis.
This is the most common genotype found in the general population across all ancestries.
Carrier of pathogenic variant
This individual carries one copy of the pathogenic variant and one functional copy of the gene. As this condition is inherited in an autosomal recessive manner, carriers typically do not exhibit the clinical symptoms of 17-alpha-hydroxylase deficiency, though they should be aware of their carrier status for family planning.
This genotype is extremely rare in the general population, as the pathogenic variant is primarily identified in clinical settings.
Pathogenic CYP17A1 deficiency
This genotype is associated with 17-alpha-hydroxylase/17,20-lyase deficiency, a condition that impairs the production of cortisol and sex steroids. Individuals with this profile may present with hypertension, hypokalemia, and primary amenorrhea or absent secondary sexual characteristics; please consult with an endocrinologist or genetic counselor to discuss these clinical findings.
This genotype is ultra-rare and is typically only identified in individuals diagnosed with congenital adrenal hyperplasia.
What is the rs121908081 Variant?
The rs121908081 variant is a specific nucleotide change identified within the human genome. In genetic databases, it is categorized as a pathogenic variant, meaning it has been documented in clinical settings as a cause for certain health conditions. This variant sits within the CYP17A1 gene, which is located on chromosome 10. Because it is an ultra-rare variant, it is not typically found in the general population at high frequencies. Geneticists and clinicians track such variants to better understand how specific changes in our DNA sequence can alter the production of proteins that are vital for normal physiological processes. When a variant is labeled as pathogenic in databases like ClinVar, it indicates that evidence from clinical testing and research studies supports its role in disrupting normal gene function.
The Role of the CYP17A1 Gene
The CYP17A1 gene provides the essential instructions for creating an enzyme known as cytochrome P450 17alpha-hydroxylase/17,20-lyase. This enzyme is a critical player in the steroidogenesis pathway, the complex series of chemical reactions that produce steroid hormones in the body. Specifically, this enzyme performs two distinct functions: 17alpha-hydroxylase activity and 17,20-lyase activity. These reactions are necessary to convert hormone precursors into glucocorticoids, which help regulate metabolism and the immune response, and sex hormones, which are vital for reproductive development. When the CYP17A1 gene contains a pathogenic mutation, the resulting enzyme may be non-functional or have significantly reduced activity. This deficiency prevents the body from producing adequate levels of these hormones, leading to the clinical manifestations associated with steroid 17alpha-hydroxylase deficiency.
Clinical Associations and Evidence
Research associates mutations in the CYP17A1 gene, including rare variants like rs121908081, with a condition known as steroid 17alpha-hydroxylase deficiency. This is a rare form of congenital adrenal hyperplasia. Clinical reports indicate that individuals with such deficiencies may experience symptoms such as hypertension, hypokalemia, and abnormal development of the genitalia. The evidence for the pathogenicity of these variants is considered moderate to strong in clinical literature, as they are identified through diagnostic testing in patients presenting with these specific endocrine symptoms. Because the condition is rare, most of the available data comes from case studies and clinical observations rather than large-scale population-wide association studies. It is important to note that the presence of a variant does not guarantee a specific health outcome, and clinical diagnosis requires professional evaluation of hormone levels and physical symptoms.
Population Frequency and Interpretation
The rs121908081 variant is classified as ultra-rare, meaning it is found in an extremely small percentage of the global population. Unlike common genetic polymorphisms that might be shared by millions, this variant is typically identified only in individuals undergoing clinical genetic testing for specific, suspected endocrine disorders. Because of its rarity, there is limited data regarding its distribution across different ancestral groups. In the context of genetic testing, finding such a variant is significant and usually requires careful interpretation by a genetic counselor or medical geneticist. It is not a variant that would typically appear on standard, direct-to-consumer ancestry or wellness reports. If you have received information about this variant from a clinical report, it is essential to discuss the findings with your healthcare provider to understand what they mean for your specific health context.
Managing Genetic Information
Genetic information regarding rare, pathogenic variants should always be handled within a clinical framework. If you or a family member have been identified as a carrier of a CYP17A1 variant, you should consult with an endocrinologist or a clinical geneticist. These professionals can provide context based on your personal and family medical history, which is crucial for interpreting the clinical significance of any genetic finding. You cannot diagnose yourself or determine your health risks based solely on a variant report. Furthermore, if this information relates to medication or hormone replacement therapy, you must discuss all treatment options and dosing with your clinician or pharmacist. They are the only ones qualified to integrate your genetic data with your clinical symptoms to provide appropriate medical guidance and care.
How common is this variant?
The rs121908081 variant is ultra-rare, with no significant frequency observed in large-scale population databases like gnomAD.
Frequently asked questions
What is steroid 17alpha-hydroxylase deficiency?
It is a rare genetic disorder caused by mutations in the CYP17A1 gene that prevents the body from producing enough cortisol and sex hormones. This can lead to symptoms like high blood pressure and issues with sexual development.
Is rs121908081 common in the general population?
No, this variant is considered ultra-rare. It is not typically found in the general population and is usually only identified through targeted clinical genetic testing.
Can I use this information to diagnose myself?
No. Genetic variants must be interpreted by a qualified healthcare professional in the context of your physical symptoms, hormone levels, and medical history. Never attempt to self-diagnose based on genetic data.
What should I do if I have this variant?
If you have been identified as having this variant, you should schedule an appointment with an endocrinologist or a genetic counselor. They can explain the clinical implications and help you manage any associated health risks.
Sources & further reading
Educational information only, last refreshed 9/22/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908081?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP17A1
Promoter polymorphism in CYP17A1 associated with altered androgen biosynthesis, hormone-sensitive cancer risk, and response to aromatase inhibitors and taxane-based chemotherapy.
This variant is associated with an increased susceptibility to aggressive forms of prostate cancer.
Loss-of-function mutation in CYP17A1 associated with combined 17-alpha-hydroxylase/17,20-lyase deficiency and primary amenorrhea.
Pathogenic variant in CYP17A1 causing 17-alpha-hydroxylase deficiency, ambiguous genitalia, and hypergonadotropic hypogonadism.